• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺髓样癌中的RET剪接位点变异

RET splice site variants in medullary thyroid carcinoma.

作者信息

Saeed-Vafa Daryoush, Chatzopoulos Kyriakos, Hernandez-Prera Juan, Cano Pedro, Saller James J, Hallanger Johnson Julie E, McIver Bryan, Boyle Theresa A

机构信息

H. Lee Moffitt Cancer Center, Tampa, FL, United States.

出版信息

Front Genet. 2024 Mar 19;15:1377158. doi: 10.3389/fgene.2024.1377158. eCollection 2024.

DOI:10.3389/fgene.2024.1377158
PMID:38566816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10985236/
Abstract

Medullary thyroid carcinoma (MTC) is an aggressive cancer that is often caused by driver mutations in . Splice site variants (SSV) reflect changes in mRNA processing, which may alter protein function. SSVs have been described in thyroid tumors in general but have not been extensively studied in MTC. The prevalence of SSVs was evaluated in 3,624 cases with next generation sequence reports, including 25 MTCs. Fisher exact analysis was performed to compare SSV frequency in cancers with/without a diagnosis of MTC. All 25 MTCs had at least one of the two most common SSVs versus 0.3% of 3,599 cancers with other diagnoses ( < 0.00001). The 11 cancers with non-MTC diagnoses that had the common SSVs were 4 neuroendocrine cancers, 4 non-small cell lung carcinomas, 2 non-MTC thyroid cancers, and 1 melanoma. All 25 MTCs analyzed had at least one of the two most common SSVs, including 4 with no identified mutational driver. The identification of SSVs in all MTCs, but rarely in other cancer types, demonstrates that these SSVs distinguish MTCs from other cancer types. Future studies are needed to investigate whether these SSVs play a pathogenic role in MTC.

摘要

甲状腺髓样癌(MTC)是一种侵袭性癌症,通常由[具体基因]中的驱动突变引起。剪接位点变异(SSV)反映了mRNA加工过程中的变化,这可能会改变蛋白质功能。一般来说,SSV已在甲状腺肿瘤中有所描述,但在MTC中尚未得到广泛研究。在3624例有下一代测序报告的病例中评估了SSV的患病率,其中包括25例MTC。进行Fisher精确分析以比较有/无MTC诊断的癌症中SSV的频率。所有25例MTC均至少有两种最常见SSV中的一种,而在3599例其他诊断的癌症中这一比例为0.3%(P<0.00001)。11例有非MTC诊断且有常见SSV的癌症分别为4例神经内分泌癌、4例非小细胞肺癌、2例非MTC甲状腺癌和1例黑色素瘤。分析的所有25例MTC均至少有两种最常见SSV中的一种,其中4例未发现突变驱动因素。在所有MTC中均发现了SSV,但在其他癌症类型中很少见,这表明这些SSV可将MTC与其他癌症类型区分开来。未来需要进行研究以调查这些SSV在MTC中是否发挥致病作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e8/10985236/9157aa7b0684/fgene-15-1377158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e8/10985236/d97f133d0f94/fgene-15-1377158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e8/10985236/9157aa7b0684/fgene-15-1377158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e8/10985236/d97f133d0f94/fgene-15-1377158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66e8/10985236/9157aa7b0684/fgene-15-1377158-g002.jpg

相似文献

1
RET splice site variants in medullary thyroid carcinoma.甲状腺髓样癌中的RET剪接位点变异
Front Genet. 2024 Mar 19;15:1377158. doi: 10.3389/fgene.2024.1377158. eCollection 2024.
2
Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.RET原癌基因点突变分析可区分遗传性与非遗传性甲状腺髓样癌。
Cancer. 1995 Aug 1;76(3):479-89. doi: 10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m.
3
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.C 细胞神经内分泌肿瘤更新:甲状腺髓样癌的预后和预测的组织病理学和分子特征。
Endocr Pathol. 2023 Mar;34(1):1-22. doi: 10.1007/s12022-023-09753-5. Epub 2023 Mar 8.
4
Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.散发性甲状腺髓样癌的肿瘤分级及与生存相关的分子特征
Thyroid. 2024 Feb;34(2):177-185. doi: 10.1089/thy.2023.0482. Epub 2023 Dec 27.
5
Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.《散发性与家族性髓样甲状腺癌的基因组学和表观基因组学研究》
Endocr Pathol. 2021 Mar;32(1):35-43. doi: 10.1007/s12022-021-09664-3. Epub 2021 Jan 25.
6
Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.对甲状腺髓样癌中的 RET、HRAS、KRAS、NRAS、BRAF、AKT1 和 CTNNB1 进行突变筛查。
Anticancer Res. 2011 Dec;31(12):4179-83.
7
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.对甲状腺髓样癌的外显子组测序揭示了 RET 和 RAS 中的显性和互斥致癌突变。
J Clin Endocrinol Metab. 2013 Feb;98(2):E364-9. doi: 10.1210/jc.2012-2703. Epub 2012 Dec 21.
8
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.RET 原癌基因突变的多样性及其在甲状腺髓样癌中的致癌机制。
Crit Rev Clin Lab Sci. 2016 Aug;53(4):217-27. doi: 10.3109/10408363.2015.1129529. Epub 2016 Jan 27.
9
Genetics of medullary thyroid cancer: An overview.甲状腺髓样癌的遗传学:概述。
Int J Surg. 2017 May;41 Suppl 1:S2-S6. doi: 10.1016/j.ijsu.2017.02.064.
10
Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.71例日本甲状腺髓样癌患者RET原癌基因的突变分析。
J Hum Genet. 1998;43(2):101-6. doi: 10.1007/s100380050048.

本文引用的文献

1
Precision oncology for -related tumors.针对 - 相关肿瘤的精准肿瘤学。 (注:原文中“-related”前缺少具体内容,翻译只能做到这样相对模糊的表述)
Front Oncol. 2022 Aug 24;12:992636. doi: 10.3389/fonc.2022.992636. eCollection 2022.
2
Higher Gene Expression Levels Do Not Represent anAlternative Activation Mechanism in Medullary Thyroid Carcinoma.高基因表达水平并不代表甲状腺髓样癌的另一种激活机制。
Biomolecules. 2021 Oct 19;11(10):1542. doi: 10.3390/biom11101542.
3
Guideline-Adherent Clinical Validation of a Comprehensive 170-Gene DNA/RNA Panel for Determination of Small Variants, Copy Number Variations, Splice Variants, and Fusions on a Next-Generation Sequencing Platform in the CLIA Setting.
在CLIA环境下,在下一代测序平台上对用于检测小变异、拷贝数变异、剪接变异和融合的170基因综合DNA/RNA检测板进行符合指南的临床验证。
Front Genet. 2021 May 20;12:503830. doi: 10.3389/fgene.2021.503830. eCollection 2021.
4
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.基于 DNA 的高度精确检测和治疗肺癌中 MET 外显子 14 跳跃突变的结果。
Lung Cancer. 2020 Feb;140:46-54. doi: 10.1016/j.lungcan.2019.11.010. Epub 2019 Nov 18.
5
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.通过下一代靶向测序研究的大量散发性甲状腺髓样癌患者队列中体细胞突变的遗传图谱
iScience. 2019 Oct 25;20:324-336. doi: 10.1016/j.isci.2019.09.030. Epub 2019 Sep 26.
6
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.RET 异构体在正常甲状腺组织、甲状腺乳头状癌和甲状腺髓样癌中的差异表达。
Endocrine. 2019 Sep;65(3):623-629. doi: 10.1007/s12020-019-01957-2. Epub 2019 Jul 5.
7
Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET.研究RET基因未突变的甲状腺髓样癌患者中RET基因的表达及启动子甲基化情况。
J Cell Physiol. 2019 Sep;234(9):16304-16311. doi: 10.1002/jcp.28295. Epub 2019 Mar 14.
8
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.基于 DNA 与基于 RNA 的肺癌 MET 外显子 14 跳跃事件检测。
J Thorac Oncol. 2019 Apr;14(4):737-741. doi: 10.1016/j.jtho.2018.12.020. Epub 2019 Jan 9.
9
RET rearrangements are actionable alterations in breast cancer.RET 重排是乳腺癌的一种可靶向改变。
Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4.
10
OncoKB: A Precision Oncology Knowledge Base.OncoKB:一个精准肿瘤知识库。
JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.